Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v3-FR
Language French French
Date Updated 2021-11-25 2021-08-20
Drug Identification Number 02350092 02350092
Brand name ACTEMRA ACTEMRA
Common or Proper name ACTEMRA ACTEMRA
Company Name HOFFMANN-LA ROCHE LIMITED HOFFMANN-LA ROCHE LIMITED
Ingredients TOCILIZUMAB TOCILIZUMAB
Strength(s) 80MG 80MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 80MG/4ML 1VIAL IV 80MG/4ML 1VIAL IV
ATC code L04AC L04AC
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2022-01-15 2021-10-31
Actual start date 2021-10-31
Estimated end date 2022-01-31 2021-12-31
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments